259 results about "Blood uric acid" patented technology

The invention discloses a compound chicory series product and a preparation method thereof. The series product is prepared from main component chicory and one or more yam rhizome, semen coicis, rhizoma smilacis glabrae, Siegesbeckia herb, longhairy antenoron herb, cutch, mulberry leaf, kudzu-vine root, barbary wolfberry fruit, poria cocos, corn stigma, guava leaf, red yeast rice, cassia seed, hawthorn, lotus leaf, aloe and nano selenium according to different applications of the product. The product has the main characteristics of synchronous adjusting effect on endocrine disorder and obvious effects on adjustment of blood uric acid, blood sugar and blood fat and immunity reinforcement, wide adaptive crowd and positive economic and social significance and is easy to realize industrialized large production.

The present invention provides lactic acid bacteria which are suitable for use for dietary products and pharmaceuticals, and which can suppress the increase of blood uric acid level.

Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2922, were found.

The invention discloses a lactobacillus plantarum UA-416 strain and application thereof, and belongs to the field of functional food microbes. Blanks of lactobacillus plantarum in the effects of lowering uric acid and resisting gout are filled up. According to the lactobacillus plantarum (Lactobacillus plantarum) UA-416 strain provided by the invention, the bacterial strain is already collected inthe China Center for Type Culture Collection (CCTCC) on July 25, 2017; the collection number is CCTCC NO: M2017419. The lactobacillus plantarum UA-416 strain provided by the invention can be used foreffectively lowering the level of blood uric acid, is used for improving the levels of urea nitrogen and creatinine and inhibiting the activity of xanthine oxidase in serum, and has prevention and treatment effects on uricemia or the gout.

The invention relates to a pain-relieving mixture for the treatment of gouty arthritis, which pertains to the field of pharmaceutical formulations, the technology is characterized in that: the parts by weight of the raw materials are: 6 to 10 percent amur corktree bark, 12 to 16 percent sevenlobed yam rhizome, 4 to 6 percent rhubarb, 8 to 12 percent Japanese honeysuckle stem, 6 to 9 percent Indian iphigenia bulb, 12 to 16 percent spreading hedyotis herb, 6 to 10 percent glabrous greenbrier rhizome, 4 to 6 percent frankincense, 4 to 6 percent myrrh, 6 to 10 percent clematis root, 6 to 10 percent largeleaf gentian root and 6 to 9 percent earthworm, and the sum of the percentages of the components of the raw materials is equal to 100 percent. The invention can effectively alleviate the symptoms of gouty arthritis, prevent and treat the repeated attacks of gouty arthritis, lower blood uric acid, have no toxicity or side effects and have definite efficacy.

The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below.

[in the formula,

• • R¹ is -Q¹-A¹ and the like; is a double bond or a single bond; when is a double bond, W¹ is a nitrogen atom or a group represented by the general formula: ═C(R^a)—, and W² is a nitrogen atom or a group represented by the general formula: ═C(R^b)—; when is a single bond, W¹ is a group represented by the general formula: —C(R^aa)(R^ab)— or a group represented by the general formula: —(C═O)—, and W² is a group represented by the general formula: —C(R^ba)(R^bb)—, a group represented by the general formula: —(C═O)— or a group represented by the general formula: —N(R^bc)—; W³, W⁴ and W⁵ are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CR^YiR^Yi′)_n; and Z is a hydroxyl group or COOR² and the like.

The invention relates to a test paper strip of using color reaction to detect the concentration of uric acid in urine. It includes test paper base material, its feature is that: enzyme color developing reagent adheres to test paper base material. The beneficial effect of this invention is that, the detector can detect the concentration of uric acid in urine in own home, so as to preliminary reach the range of uric acid content in the urine, thus it is certain guiding significance for the blood uric acid content.

The invention discloses a method for building an animal model with hyperuricemia-combined diabetes. The method comprises the following steps: 1) feeding an target animal with fodder containing 10% (by mass) of yeast powder; subjecting the target animal to a lavage with a 4% (by mass) adenine water solution according to the following dosage of 100 milligram of adenine per day per kilogram of body weight until the blood uric acid level of the target animal starts falling; 2) halving the dosage of the adenine water solution in step 1), subjecting the target animal to a subcutaneous injection with an oteracil potassium emulsion twice a day according to the following dosage of 100 milligram of oteracil potassium emulsion per day per kilogram of body weight until the target animal shows clinical symptoms of diabetes, and then obtaining the animal model with the hyperuricemia-combined diabetes. The method builds the animal model with the hyperuricemia-combined diabetes for the first time, the animal model has typical disease symptoms, the quantity index has statistical significance, and studies such as glucose clamp test and immunohistochemistry also prove that the modeling is successful. Therefore, the method for building the animal model with the hyperuricemia-combined diabetes is a reliable and practical technique.

The invention belongs to the field of traditional Chinese medicines, relates to traditional Chinese medicines and health care preparations, and especially relates to a medicinal food formula and a medicinal edible preparation for preventing and treating hyperuricemia and gout. The medicinal edible preparation comprises traditional Chinese medicines or active ingredients of 10 to 80 parts of plantain seed and 10 to 80 parts of semen cuscutae. The medicinal edible preparation is prepared from extract of plantain seed and semen cuscutae, and auxiliary materials, and can be processed into tablets, pills, electuary, an oral liquid, a tea bag and a health-care food additive. An animal acute toxicity test and a sub-chronic toxicity test prove that the medicinal edible preparation is safe and has no toxic or side effect. A pharmacodynamic animal test proves that the medicinal edible preparation can obviously reduce blood uric acid and improve kidney uric acid crystallization and injuries. The medicinal edible preparation as a treatment drug or a health-care product can be used for patients suffering from hyperuricemia and gout, can obviously reduce a blood uric acid level and relieve gouty arthritis symptoms, and has good safety.

Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found.

The invention relates to a Chinese medicinal composition for reducing blood uric acid. The Chinese medicinal composition consists of active ingredient extracts prepared from glabrous greenbrier rhizome and oriental water plantain rhizome serving as raw materials and medicinal dressing, and can be prepared into various medicinally acceptable preparations and injection. The Chinese medicinal composition has the effects of removing dampness, releasing toxin and benefiting joints, and is mainly used for gouty arthritis and hyperuricemia.

The present invention provides a new application of Fraxinus general counmarin and aesculetin as the extractives of Chinese medicine material cortex Fraxini. The said two has obvious effects of stopping pain, resisting inflammation and reducing blood uric acid. They has obvious curative effect on acute and chronic gout and no obvious toxic side-effect. The present invention also provides a simple preparation process of Fraxinus general coumarin, and that is a Fraxinus general coumarin concentrating and purifying process.

The invention relates to a PEGylation urate oxidase compound as well as the preparation method thereof and the preparation of PEGylation urate oxidase compound as well as the application thereof, particularly relates to a PEGylation urate oxidase compound which has extremely low immunogenicity and anaphylaxis, can be applied repetitively and has a long acting as well as the preparation method thereof and the preparation of PEGylationurate oxidasee compound as well as the application thereof. The invention adopts a modification method which has high selectivity to a N-terminal of a urate oxidase, which means that PEG active ester is connected with the N-terminal of the urate oxidase by covalence bond, the uniformity of products is greatly improved, the products are easy to be purified, the activity of the purified products can be better preserved and the immunogenicity of prototype protein of the urate oxidase can be reduced obviously. The PEGylation urate oxidase compound can prevent systemic anaphylaxis when applied, can be applied repetitively and has the efficacy of treating and preventing gout, reducing the level of serum uric acid, preventing tumor lysis syndrome and improving the renal function.

The invention relates to the field of microorganisms, and discloses lactobacillus fermentum capable of reducing blood uric acid. The strain is named 2644 strain, and is preserved at the China GeneralMicrobiological Culture Collection Center on 19th, November, 2018, and a microbial preservation number is CGMCC NO.16754; and the preservation authority address is NO.3 1# Courtyard, Beichen West Road, Chaoyang District, Beijing, and the microorganism is classified and named Lactobacillus fermentum. The strain can effectively reduce the content of the blood uric acid; and not only can intake of exogenous purines be reduced, but also discharge of internal uric acid from an intestinal tract can be promoted so that the blood uric acid level of a body can be more effectively controlled.

The invention discloses lactobacillus brevis DM9218 capable of decomposing purine nucleoside with high decomposition rate at high speed and reducing blood uric acid, a gene segment and a recombinant protein. The lactobacillus brevis DM9218 (Lactobacillus brevis) is preserved in China General Microbiological Culture Collection Center with the preservation number being CGMCC NO.12797; the gene segment of the lactobacillus brevis DM9218 has a DNA (Deoxyribonucleic Acid) sequence as shown in SEQ ID NO:2; the recombinant protein of the gene segment of the lactobacillus brevis DM9218 is obtained through adopting a DNA of the lactobacillus brevis DM9218 as a template for PCR (Polymerase Chain Reaction), and utilizing a gene cloning method for a PCR product, wherein DNA sequences of an upstream primer and a downstream primer of PCR reaction are respectively as shown in SEQ ID NO:3 and SEQ ID NO:4.

The invention relates to a medicine for treating gout, in particular relates to a traditional Chinese medicine which is prepared from a plant Chinese herb and is used for treating the gout. The traditional Chinese medicine for treating the gout comprises the following components: astragalus, white peony root, coix seed, semen plantaginis, notopterygium, arisacma consanguineum, yam rhizome, angelica sinensis, rhizoma smilacis glabrae, divaricate saposhnikovia root, radix clematidis, cinnamon, nidus vespae and christina loosestrife herb. All the medicines are mixed and complete one another, so that the traditional Chinese medicine has the effects of clearing away heat and toxicity, activating blood to remove stasis, eliminating carbuncle, eliminating swelling, activating meridians to stop pain, inducing diuresis to reduce edema, tonifying spleen, dehumidifying, relaxing the muscles, eliminating numbness and the like; through the synergistic effect of the medicines, uric acid discharging in the body is promoted, and symptoms are eliminated; the action of blood uric acid is reduced, and the gout is effectively treated.

The invention discloses a traditional Chinese medicine composition for treating gouty arthritis. According to the traditional Chinese medicine, gouty arthritis belongs to the domain of 'arthralgia syndrome'. The disease is caused by endoretention of damp heat, detained skeleton, poor qi-blood circulation, stagnation leading to pain caused by overfeeding of greasy and surfeit flavor usually, resulting vital energy and blood retained at the local part of the scleromere, glow and swelling. Thus, the traditional Chinese medicines, namely euphorbia thymifolia, tuckahoe, yam rhizome, tonkin pepper herb, tree falsespiraea bark, siphon, delavay violet root, featherycleft horsegentian root, caulis lonicerae, herba ajugae, honeysuckle stem, herba ajugae, and rhizoma curculiginis are selected, and prepared into soup by a manufacturing laboratory in a hospital. The clinical test shows that the total effective rate achieves 96.9%; the blood uric acid is obviously reduced; the traditional Chinese medicine composition is worthy of clinical application.

The invention discloses application of plum extract in gout. The application can be realized by decreasing blood uric acid, reducing blood fat and/or inhibiting inflammation. The invention also discloses application of plum extract in treating and preventing hyperuricemia, and the application can result in effects of treating or preventing gout.

A food composition and pharmaceutical composition with strains of lactic acid bacteria for reducing blood uric acid concentration are provided, comprising at least one or two isolated lactic acid bacteria strains selected from the following two: TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri).

The invention discloses lactobacillus fermentum for preventing and treating hyperuricemia as well as a composition and application thereof, wherein the lactobacillus fermentum GF1800 for preventing and treating hyperuricemia has the preservation number of CCTCC NO:M 2021984. The lactobacillus fermentum GF1800 is high in biological activity and strong in acid production capacity, can effectively inhibit the activity of pathogenic microorganisms and xanthine oxidase, can tolerate gastric acid and cholate, has a remarkable degradation effect on nucleoside substances, uric acid, cholesterol, nitrite and the like, can efficiently inhibit intake of exogenous uric acid and increase of endogenous uric acid, can obviously reduce the blood uric acid level of hyperuricemia, and meanwhile, improves intestinal and kidney structural injury and inflammatory response. The invention further discloses a composition containing the lactobacillus fermentum GF1800 and a strain metabolite and postbiotics of the lactobacillus fermentum GF1800 and an application of the lactobacillus fermentum GF1800 and the postbiotics of the lactobacillus fermentum GF1800 to preparation of functional food or medicine for preventing and treating hyperuricemia or/and gout, degrading nucleoside, inhibiting xanthine oxidase, reducing cholesterol, degrading nitrite and inhibiting pathogenic bacteria.

The invention belongs to the technical field of food preparation, and particularly relates to a fructus gardeniae and poria cocos composite beverage and a preparation method thereof. The fructus gardeniae and poria cocos composite beverage is prepared from the following raw materials of fructus gardeniae, poria cocos, villous amomum fruits, chicory, mulberry leaves, corn stigma, polished glutinousrice, Chinese yams, cherries, carrots, celery, papayas, lemons, potassium citrate, sodium citrate, water and lactic acid bacteria. The fructus gardeniae and poria cocos composite beverage is suitablefor patients suffering from hyperuricaemia and gout, in multiple manners for invigorating spleen, eliminating dampness, promoting drainage of uric acid, reducing uric acid and the like, the blood uric acid level can be reduced in multiple target points, and the breaking out of the gout can be alleviated.